

Oral Presentations at 2022 ASCO Annual Meeting

Friday, June 3, 2022

Note: all times listed are Eastern Time

Presentation	Speaker	Session/Time
Understanding Bias and Microaggression	Narjust Duma, MD	Education Session: Microaggression, Bias and Equity in the Workplace June 3, 2:00 pm
Genomic Profiling for Treatment Decision in Patients With Metastatic Breast Cancer	Nikhil Wagle, MD	Education Session: Molecular Testing for Patients with Breast Cancer June 3, 2:00 pm
Prevention and Treatment of Brain Metastases	Nancy U. Lin, MD	Education Session: Management of HER2- Overexpressing Metastatic Breast Cancer June 3, 5:30 pm

Saturday, June 4, 2022

Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer (CHiRP) (Abstract 103)	Marla Lipsyc-Sharf, MD	Clinical Science Symposium: ctDNA: Dawn of a New Era June 4, 9:00 am
Cultural Humility in Engaging Patient Spirituality in End-of-Life Care	Tracy A. Balboni, MD, MPH	Education Session: Knowing What We Don't Know: The Importance of Cultural Humility in Delivering High-Quality Care June 4, 9:00 am
Neoadjuvant Immunotherapy: Does the Presence of the Primary Tumor Improve Activation of New T-Cell Clones?	Elizabeth A. Mittendorf, MD, PhD	Education Session: Bringing Immunotherapy Into the Curative Setting June 4, 9:00am



Oral Presentations at 2022 ASCO Annual Meeting

Saturday, June 4, 2022

Note: all times listed are Eastern Time

Presentation	Speaker	Session/Time
Novel Therapeutic Approaches in Acute Lymphoblastic Leukemia in Older Adults	Marlise Rachael Luskin, MD	Education Session: Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum June 4, 5:45 pm
Small Molecule Inhibition of KRAS: Opportunities and Challenges	Andrew Aguirre, MD, PhD	Education Session: Targeting KRAS in Upper Gastrointestinal Malignancies: The Holy Grail June 4, 5:45pm

Sunday, June 5, 2022

Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial (Abstract LBA4)	Paul Richardson, MD	Plenary Session June 5, 2:00 pm
Updates on Abstract 360922: <i>A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial</i>	Wendy Y. Chen, MD, MPH	Education Session: ASCO Plenary Series: Rapid Abstract Updates June 5, 5:30 pm
High-Risk Neuroblastoma: Current Approaches and Challenges	Steven G. DuBois, MD	Education Session: High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes June 5, 5:30pm



Oral Presentations at 2022 ASCO Annual Meeting

Monday, June 6, 2022

Note: all times listed are Eastern Time

Presentation	Speaker	Session/Time
Implementing systematized patient-facing Lynch syndrome (LS) risk assessment in oncology using the electronic health record (EHR) system (Abstract 10503)	Chinedu Ukaegbu, MBBS, MPH	Oral Abstract Session: Prevention, Risk Reduction and Hereditary Cancer June 6, 9:00 am
Treatment of Breast Cancer in Young Adults	Ann H. Partridge, MD, MPH	Education Session: Treatment of Solid Cancers in Young Adults: Sarcoma, Breast Cancer, and Colorectal Cancer in Patients Age 18 to 40 June 6, 10:45 am
Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (Abstract 2004)	David A. Reardon, MD	Oral Abstract Session: Central Nervous System Tumors June 6, 12:30 pm
Advances in the Treatment of Waldenstrom Macroglobulinemia	Jorge Castillo, MD	Education Session: The Less-Discussed Plasma Cell Dyscrasias June 6, 2:15 pm
Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children's Oncology Group clinical trials (Abstract 10005)	Puja J. Umaretiya, MD	Oral Abstract Session: Pediatric Oncology June 6, 4:00 pm
Remote patient-reported symptoms and passive activity monitoring to improve patient-clinician communication regarding symptoms and functional status: A randomized controlled trial (PROStep) (Abstract 1506)	Christopher Manz, MD, MSHP	Oral Abstract Session: Care Delivery and Regulatory Policy June 6, 4:00 pm



Oral Presentations at 2022 ASCO Annual Meeting

Tuesday, June 7, 2022

Note: all times listed are Eastern Time

Presentation	Speaker	Session/Time
Taking on Goliath: Targeting KRAS in Non-Small Cell Lung Cancer	Jia Luo, MD	Education Session: Overcoming KRAS-Mutant Lung Cancer June 7, 9:00 am
Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT (Abstract 508)	Meredith Regan, ScD	Oral Abstract Session: Breast Cancer - Local/Regional/Adjuvant June 7, 10:45 am
Measurement of endocrine activity (SET2,3) related to prognosis and prediction of benefit from dose-dense (DD) chemotherapy in estrogen receptor-positive (ER+) cancer: CALGB 9741 (Alliance) (Abstract 505)	Otto Metzger, MD	Oral Abstract Session: Breast Cancer - Local/Regional/Adjuvant June 7, 10:45 am